SPEEDX
30.6.2021 10:21:09 CEST | Business Wire | Press release
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005407/en/
“This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”
Throughout the past year of COVID-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary Plex PCR® technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.
“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the COVID pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About MolGen
MolGen is global total solution provider of innovative extraction DNA / RNA technology, system, products and kits for human and animal diagnostics, the agriculture and biotech industries which reduce hands-on time and increase productivity while maintaining high yields and reproducibility.
From sample to result, MolGen is challenging the status quo in molecular diagnostics by offering platform stand-alone systems and consumables. Highly customizable, MolGen’s portfolio offers the perfect workflow for our customers’ specific needs, being high-quality, adaptable and safe.
Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005407/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Procore Redefines the Common Data Environment with Connected Data and Agentic AI1.6.2026 10:00:00 CEST | Press release
CDE unifies project data, workflows, BIM models, and asset information in one trusted environment—creating the foundation for AI agents to amplify the reach of construction teams Procore is the solution to fragmented data, helping ensure information integrity from approved design to handover Connects the full project lifecycle in one trusted environment with a single source of truth across BIM, Documents, Quality, and Assets Transforms BIM into a live execution workspace via BIM Model Manager, streaming models of any size directly to mobile devices to connect real-time project data with 3D coordination Leverages Procore AI with embedded Datagrid capabilities to turn project data into an actionable foundation, powering agentic AI coworkers that can help automate construction workflows and execute work directly within the platform Procore Technologies, Inc. (NYSE: PCOR), the leading global provider of construction management software, today announced the launch of its connected Common Da
AI Investment Boom Across the UK is Fuelled More by Fear of Missing out Than Actual Results, According to Expereo1.6.2026 10:00:00 CEST | Press release
Enterprises are investing aggressively in AI to avoid being left behind – but less than a quarter say AI implementations have exceeded expectations, often due to inadequate networks Enterprise AI spending is climbing rapidly, with boards racing to deploy the technology faster than they can measure whether it works. According to the latest IDC InfoBrief, commissioned by Expereo*, around 70% of organizations are investing in AI, motivated by its potential or by the fear of falling behind the competition, but they lag in disciplined ROI evaluation, and one in five (20%) admit they are investing aggressively in AI with little evaluation, driven by the fear of being left behind. The IDC InfoBrief, based on a survey of 800 technology leaders across Europe, the US, and APAC, found that AI has become one of the most prioritized technology investments globally. When asked which technologies their organization will prioritize in terms of effort and/or financial investment over the next 12 months
Corient Completes Acquisitions of Stonehage Fleming and Stanhope Capital Group; Global Assets Surpass US$500 Billion1.6.2026 08:15:00 CEST | Press release
Corient becomes the world’s largest non-bank wealth manager and multi-family office focused on serving ultra-high- and high-net-worth clients. Corient today announced the successful completion of its previously announced acquisitions of Stonehage Fleming and Stanhope Capital Group, marking a significant milestone in its continued global expansion. “This is an exciting moment for Corient and the clients we serve around the world,” said Kurt MacAlpine, Founding Partner and Chief Executive Officer of Corient. “We are thrilled to welcome our new Partners at Stonehage Fleming and Stanhope Capital Group to Corient as we continue building a truly global firm defined by partnership, collaboration and an unwavering commitment to client excellence.” With today’s announcement, Corient becomes the world’s largest non-bank wealth manager and multi-family office focused on ultra-high- and high-net-worth clients. The firm, established in 2020, operates under a client-first approach with complete fee
New Report From King: Mobile Games Sector Is Strategic Growth Driver for Europe, Contributing €6BN and Supporting 63,000+ Jobs1.6.2026 08:00:00 CEST | Press release
New report shows that more than 1,000 European mobile games studios contributed almost €6 billion to the European economy in 2025, supported more than 63,000 jobs1, and generated €7.53 billion in revenue from global audiences in 2025Mobile games are now the most popular way to play, accounting for 55% of global video games revenue, underlining their importance to Europe’s creative and digital economy King, the leading interactive entertainment company behind Candy Crush Saga, has today launched a first-of-its-kind report celebrating mobile games as a European success story,and spotlighting the sector’s contribution to jobs, growth, creativity and digital innovation across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529376748/en/ The report,Mobile Matters: The Impact of Mobile Games for Europe, shows that in 2025 Europeanmobile games companies contributed an estimated €5.89 billion in economic value (GVA) to
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom